STOCK TITAN

Alimera Sciences, Inc. - $ALIM STOCK NEWS

Welcome to our dedicated page for Alimera Sciences news (Ticker: $ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alimera Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alimera Sciences's position in the market.

Rhea-AI Summary

Alimera Sciences, Inc. (Nasdaq: ALIM) announced the presentation of three scientific abstracts at upcoming ophthalmic congresses. The abstracts will focus on safety outcomes and retinal thickness related to the 0.18 mg Fluocinolone Acetonide Intravitreal Implant in patients with Chronic Non-infectious Uveitis. The conferences include the ARVO and RWC, showcasing research by renowned physicians in the field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
none
-
Rhea-AI Summary

Alimera Sciences, a global pharmaceutical company, will report its first quarter 2024 financial results on May 14, 2024, and hold a conference call at 9:00 AM ET on the same day to discuss financial performance and corporate updates. Participants can register for the conference call online or dial-in directly. A webcast replay will be available after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences earnings
-
Rhea-AI Summary
Alimera Sciences, Inc. announces inducement grants under the 2024 Equity Inducement Plan for new executive appointments, including restricted stock units and stock options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none
Rhea-AI Summary
Alimera Sciences, Inc. announces the initiation of a randomized clinical trial studying ILUVIEN for the prevention of visual acuity loss due to radiation retinopathy. The study aims to evaluate the effectiveness of faricimab injections versus observation in patients with primary choroidal melanoma undergoing plaque brachytherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) reports impressive Q4 net revenue growth of 88% to $26.3 million and full-year net revenue up 49% to $80.8 million in 2023. The company also raises its 2024 revenue guidance, showcasing strong performance in marketing ILUVIEN and YUTIQ products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
Alimera Sciences, Inc. (ALIM) will report its fourth quarter and full year 2023 financial results on March 7, 2024, before the market opens. A conference call will be held at 9:00 AM ET on the same day to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences earnings
Rhea-AI Summary
Alimera Sciences, Inc. (ALIM) announces that the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending that patients with a natural lens being treated for chronic diabetic macular edema (DME) have access to ILUVIEN, a sustained-release treatment lasting up to 36 months. This recommendation could potentially benefit up to 75% of the overall DME population in the United Kingdom. NHS England and NHS Wales are expected to provide funding for this guidance shortly after publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) has completed enrollment for the Synchronicity Study, evaluating the safety and efficacy of YUTIQ in the treatment of chronic non-infectious uveitis and related intraocular inflammation. The Phase 4 open-label study aims to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment. The initial readout from the study is expected in the second half of next year and could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Elliot Maltz, C.P.A., as Chief Financial Officer. Mr. Maltz brings extensive experience from public international commercial-stage companies and will play a key role in enhancing the company's growth trajectory and driving improved cash flow. The company also approved an inducement option to purchase up to 75,000 shares of common stock for Mr. Maltz.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Todd Wood as President U.S. effective immediately. Mr. Wood brings extensive commercial leadership experience from the pharmaceutical and medical device industries, including leading the eye care sales organization at Allergan. The company also granted an inducement option to purchase up to 125,000 shares of common stock to Mr. Wood.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
management
Alimera Sciences, Inc.

Nasdaq:ALIM

ALIM Rankings

ALIM Stock Data

186.98M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ALPHARETTA

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.